Jeddah, KSA, February 19, 2024 - Gilead Sciences, a global biopharmaceutical powerhouse, has inked a Memorandum of Understanding (MoU) with the Saudi Oncology Society (SOS). The partnership, spanning three years initially, aims to elevate oncology care standards in Saudi Arabia.
The collaboration focuses on research, clinical trials, medical education, and scientific exchange. Gilead Sciences, committed to fostering a healthier world through scientific advancements, envisions a transformative journey with SOS. Together, they aim to address unmet needs in oncology, optimizing treatment management, and directing patients to specialized healthcare professionals.
Vitor Papao, General Manager of Gilead Sciences Middle East, emphasized the significance of collaborating with leading oncologists and institutions. He stated, "Our partnership with the Saudi Oncology Society reflects our dedication to supporting healthcare professionals, enhancing patient outcomes, and strengthening Saudi Arabia's healthcare system."
The MoU underscores the shared commitment of Gilead Sciences and SOS to make meaningful contributions to oncology. Dr. Meteb Al-Foheidi, Chairperson of the Saudi Oncology Society, expressed pride in embarking on this transformative journey. He said, "We look forward to making meaningful contributions to the field of oncology and improving the broader healthcare landscape in Saudi Arabia."
The strategic alliance will see regular meetings between Gilead Sciences and SOS to align and roll out initiatives. The partnership emphasizes education, research, awareness, and treatment optimization. The objective is to support healthcare professionals, enhance patient outcomes, and contribute to Saudi Arabia's broader healthcare ecosystem.
As part of the collaboration, Gilead Sciences will leverage its clinical development expertise to ensure patients receive groundbreaking therapies promptly. The company, with a strong commitment to the region, will continue working closely with local partners.